The NS5A replication complex inhibitor Daclatasvir (Daklinza), has been approved by the U.S. Food and Drug Administration (FDA), Bristol-Myers Squibb Company announced Friday. The approval was for treatment of patients with difficult-to-treat genotype 3 hepatitis C (HCV), in combination with sofosbuvir (Sovaldi), a viral NS5B polymerase blocker. Daclatasvir is the first chronic hepatitis C virus… Read more
If you arenÃ¢â‚¬â„¢t familiar with Hepatitis A you should be. ThereÃ¢â‚¬â„¢s a misconception about who is at risk, and although it is considered the least serious it still is serious. LetÃ¢â‚¬â„¢s start with a look at the history of Hepatitis A.
Hepatitis is believed to date all the way back to ancient times. It was described a disease of the liver that caused the skin to yellow. It was in 1963 that serum hepatitis was identified and labeled Hepatitis B or HBV.
It took another ten years for Hepatitis A or HAV to be identified, and until 1989 for Hepatitis C or HCV to be isolated. Since then there have been other Hepatitis viruses identified.
Hepatitis A Identified
Once Hepatitis A was identified it was also better understood. Although the history of Hepatitis A dates it back to early times they didnÃ¢â‚¬â„¢t know what it was or how to treat it. Hepatitis inflammation of the liver Ã¢â‚¬â€œ hepar = liver and itis = inflammation.